Patents Assigned to ZymoGenetics, Inc.
  • Method for treating inflammation
    Patent number: 7364732
    Abstract: A method for treating IL-20 induced inflammation. An antagonist to IL-20 is administered to treat inflammation and associated diseases. The antagonist can be an antibody that binds to IL-20 or its receptor or a soluble receptor that binds to IL-20. Examples of such diseases are adult respiratory disease, psoriasis, eczema, contact dermatitis, atopic dermatitis, septic shock, multiple organ failure, inflammatory lung injury, bacterial pneumonia, inflammatory bowel disease, rheumatoid arthritis, asthma, ulcerative colitis and Crohn's disease.
    Type: Grant
    Filed: July 19, 2006
    Date of Patent: April 29, 2008
    Assignee: ZymoGenetics, Inc.
    Inventors: Penny Thompson, Hal Blumberg, Yasmin A. Chandrasekher
  • TML polynucleotides
    Patent number: 7354739
    Abstract: The present invention is directed to polynucleotides, peptides, variants, and uses thereof for a novel peptide fragment designated TML peptides. Binding of the peptide fragment has been shown in kidney and small intestine. The present invention further includes agonists, antagonists, variants, antibodies, host cells expressing the cDNA encoding the novel TML peptides and methods for increasing gastric motility and secretion of digestive proteins and hormones using the novel TML peptides.
    Type: Grant
    Filed: June 27, 2003
    Date of Patent: April 8, 2008
    Assignee: ZymoGenetics, Inc.
    Inventors: Paul O. Sheppard, Theresa A. Deisher, Stephen R. Jaspers, Paul D. Bishop
  • Mouse cytokine receptor Zcytor16
    Patent number: 7351555
    Abstract: Cytokines and their receptors have proven usefulness in both basic research, animal models, and as therapeutics. The present invention provides a new cytokine receptor designated as “mouse Zcytor16,” which can bind and antagonize the IL-TIF cytokine.
    Type: Grant
    Filed: January 28, 2005
    Date of Patent: April 1, 2008
    Assignee: ZymoGenetics, Inc.
    Inventors: Scott R. Presnell, Wenfeng Xu, Wayne Kindsvogel, Zhi Chen
  • Use of IL-28 and IL-29 to treat cancer and autoimmune disorders
    Patent number: 7351689
    Abstract: Methods for treating patients with cancer and autoimmune disorders using IL-28 and IL-29 molecules. The IL-28 and IL-29 molecules include polypeptides that have homology to the human IL-28 or IL-29 polypeptide sequence and proteins fused to a polypeptide with IL-28 and IL-29 functional activity. The molecules can be used as a monotherapy or in combination with other known cancer and/or autoimmune therapeutics.
    Type: Grant
    Filed: July 29, 2005
    Date of Patent: April 1, 2008
    Assignee: ZymoGenetics, Inc.
    Inventors: Sean Doyle, Kevin M. Klucher, Pallavur V. Sivakumar, Wayne R. Kindsvogel, Chung Chan
  • Growth factor homolog ZVEGF4
    Patent number: 7323446
    Abstract: Polypeptide growth factors, methods of making them, polynucleotides encoding them, antibodies to them, and methods of using them are disclosed. The polypeptides comprise an amino acid segment that is at least 70% identical to residues 52-179 of SEQ ID NO:2 or residues 258-370 of SEQ ID NO:2. Multimers of the polypeptides are also disclosed. The polypeptides, multimeric proteins, and polynucleotides can be used in the study and regulation of cell and tissue development, as components of cell culture media, and as diagnostic agents.
    Type: Grant
    Filed: October 17, 2006
    Date of Patent: January 29, 2008
    Assignee: ZymoGenetics, Inc.
    Inventors: Teresa Gilbert, Charles E. Hart, Paul O. Sheppard, Debra G. Gilbertson
  • Use of interleukin-24 to treat ovarian cancer
    Patent number: 7323164
    Abstract: The present invention relates to the anti-cancer activity of IL-24 polypeptide molecules. IL-24 is a cytokine involved in inflammatory processes and human disease. The present invention includes Use of IL-24 for decreasing proliferation of ovarian cancer cells, treating ovarian cancer, amongst other uses disclosed. IL-24 polypeptides can be administered alone, or can be fused to cytotoxic moieties, and can be administered in conjunction with radiation or chemotherapeutic agents.
    Type: Grant
    Filed: April 8, 2003
    Date of Patent: January 29, 2008
    Assignee: ZymoGenetics, Inc.
    Inventors: Yasmin A. Chandrasekher, Patricia A. McKernan
  • METHODS FOR TREATING AUTOIMMUNE DISEASES USING A TACI-IG FUSION MOLECULE
    Publication number: 20070274984
    Abstract: In various embodiments, the present invention provides methods and compositions for treatment of autoimmune diseases, including rheumatoid arthritis, for example comprising administering to a patient in need of such treatment a TACI-Ig fusion molecule. In one embodiment, the TACI-Ig fusion molecule is administered in amount sufficient to slow, suppress or inhibit proliferation-inducing functions of BlyS and APRIL.
    Type: Application
    Filed: May 15, 2007
    Publication date: November 29, 2007
    Applicants: ARES TRADING S.A., ZYMOGENETICS, INC.
    Inventors: Herve Broly, Jennifer Visich, Ivan Nestorov, Sharon Busby, Jane Gross
  • Beta-defensins
    Patent number: 7294613
    Abstract: The present invention relates to polynucleotide and polypeptide molecules for zamp1, a novel member of the ?-defensin family. The polypeptides, and polynucleotides encoding them, exhibit anti-microbial activity and may be used in the study or treatment of microbial infections. The present invention also includes antibodies to the zamp1 polypeptides.
    Type: Grant
    Filed: March 5, 2002
    Date of Patent: November 13, 2007
    Assignee: ZymoGenetics, Inc.
    Inventors: David A. Adler, James L. Holloway, Nand Baindur, Stephanie Beigel-Orme, Paul O. Sheppard
  • Uses of human Zven proteins and polynucleotides
    Patent number: 7291589
    Abstract: The present invention provides methods of using Zven1 and Zven2 polypeptides to increase chemokine production. The present invention also provides methods for treating intestinal motility disorders and improving gastrointestinal function with Zven1 and Zven2 polypeptides.
    Type: Grant
    Filed: October 7, 2003
    Date of Patent: November 6, 2007
    Assignee: ZymoGenetics, Inc.
    Inventors: Penny J. Thompson, Katherine E. Lewis, Richard M. Garcia
  • Methods of treating autoimmune diseases using IL-21
    Patent number: 7276478
    Abstract: Administration of IL-21 results in decreasing autoimmune responses and thereby provides a beneficial treatment for autoimmune diseases. Specific autoimmune diseases that may be treated include multiple sclerosis, rheumatoid arthritis, systemic lupus erythematosus, psoriasis, ankylosing spondilitis, scleroderma, Type I diabetes, psoriatic arthritis, osteoarthritis, inflammatory bowel disease, atopic dermatitis and asthma. Pharmaceutical compositions can include IL-21 polypeptides and active fragments thereof.
    Type: Grant
    Filed: September 27, 2004
    Date of Patent: October 2, 2007
    Assignee: ZymoGenetics, Inc.
    Inventors: Pallavur V. Sivakumar, Andrew J. Nelson
  • secretory signal
    Patent number: 7271255
    Abstract: Novel Pichia methanolica secretory signal polypeptides, polynucleotides encoding the polypeptides, and related compositions and methods of using are disclosed. Methods of producing large amounts of recombinant proteins by employing DNA constructs having a polypeptide of interest preceded by a novel Pichia methanolica secretory signal sequence.
    Type: Grant
    Filed: February 2, 2007
    Date of Patent: September 18, 2007
    Assignee: ZymoGenetics, Inc.
    Inventors: Christopher K. Raymond, Michael R. Stamm
  • Mammalian cytokine-like polypeptide-10
    Patent number: 7271246
    Abstract: A mammalian cytokine-like polypeptide, called Mammalian Cytokine-like polypeptide-10, (Zcyto10), polynucleotides encoding the same, antibodies which specifically bind to the polypeptide, and anti-idiotypic antibodies which bind to the antibodies. Zcyto10 is useful for promoting the healing of wounds and for stimulating the proliferation of platelets.
    Type: Grant
    Filed: July 20, 2006
    Date of Patent: September 18, 2007
    Assignee: ZymoGenetics, Inc.
    Inventors: Darrell C. Conklin, Betty A. Haldeman, Angelika Grossmann
  • Human cytokine receptor
    Patent number: 7265203
    Abstract: Cytokines and their receptors have proven usefulness in both basic research and as therapeutics. The present invention provides a new human cytokine receptor designated as “Zcytor16.
    Type: Grant
    Filed: October 19, 2004
    Date of Patent: September 4, 2007
    Assignee: ZymoGenetics, Inc.
    Inventors: Scott R. Presnell, Wenfeng Xu, Wayne Kindsvogel, Zhi Chen, Steven D. Hughes
  • Anti-IL-TIF antibodies and methods of making
    Patent number: 7265211
    Abstract: The present invention relates to blocking the activity of IL-TIF polypeptide molecules. IL-TIF is a cytokine involved in inflammatory processes and human disease. The present invention includes anti-IL-TIF antibodies and binding partners, as well as methods for antagonizing IL-TIF using such antibodies and binding partners in IL-TIF-related human inflammatory diseases, amongst other uses disclosed.
    Type: Grant
    Filed: March 24, 2003
    Date of Patent: September 4, 2007
    Assignee: ZymoGenetics, Inc.
    Inventors: Wenfeng Xu, Wayne Kindsvogel, Steven D. Hughes, Yasmin A. Chandrasekher
  • Hybrid vector having a cytomegalovirus enhancer and myeloproliferative sarcoma virus promoter
    Patent number: 7262025
    Abstract: An expression vector capable of expressing high levels of heterologous proteins having a cytomegalovirus (CMV) enhancer 5? upstream from a myeloproliferative sarcoma virus (MPSV) promoter.
    Type: Grant
    Filed: June 18, 2003
    Date of Patent: August 28, 2007
    Assignee: ZymoGenetics, Inc.
    Inventor: Margaret Dow Moore
  • Interferon-like protein Zcyto21
    Patent number: 7253261
    Abstract: The present invention relates to polynucleotide and polypeptide molecules for Zcyto21, an interferon-like protein, which is most closely related to interferon-? at the amino acid sequence level. The present invention also includes antibodies to the Zcyto21 polypeptides, and methods of using the polynucleotides and polypeptides.
    Type: Grant
    Filed: August 27, 2004
    Date of Patent: August 7, 2007
    Assignee: ZymoGenetics, Inc.
    Inventors: Paul O. Sheppard, Scott R. Presnell, Brian A. Fox, Teresa Gilbert, Betty A. Haldeman, Francis J. Grant
  • Interferon-like protein Zcyto21
    Patent number: 7252969
    Abstract: The present invention relates to polynucleotide and polypeptide molecules for Zcyto21, an interferon-like protein, which is most closely related to interferon-? at the amino acid sequence level. The present invention also includes antibodies to the Zcyto21 polypeptides, and methods of using the polynucleotides and polypeptides.
    Type: Grant
    Filed: August 27, 2004
    Date of Patent: August 7, 2007
    Assignee: ZymoGenetics, Inc.
    Inventors: Paul O. Sheppard, Scott R. Presnell, Brian A. Fox, Teresa Gilbert, Betty A. Haldeman, Francis J. Grant
  • IL-21 production in prokaryotic hosts
    Patent number: 7250274
    Abstract: The expression vectors and methods using an E. coli expression system for the large scale production of IL-21 are described. The vectors utilize the IL-21 coding sequence with specific changes in nucleotides in order to optimize codons and mRNA secondary structure for translation in E. coli. Using the expression vectors, the IL-21 gene was produced in E. coli to a level of greater than 1 g/L in fed batch fermentation. Also included are OmpT deficient E. coli strains transformed with an IL-21 expression vector.
    Type: Grant
    Filed: December 12, 2003
    Date of Patent: July 31, 2007
    Assignee: ZymoGenetics, Inc.
    Inventors: Chung Chan, Bruce L. Zamost, Douglas C. Covert, Hong Y. Liu, Karen S. De Jongh, Jeffrey D. Meyer, Susan D. Holderman
  • Use of interleukin-19 to treat cervical cancer
    Patent number: 7247444
    Abstract: The present invention relates to the anti-cancer activity of IL-19 polypeptide molecules. IL-19 is a cytokine involved in inflammatory processes and human disease. The present invention includes Use of IL-19 for decreasing proliferation of cervical cancer cells, treating cervical cancer, amongst other uses disclosed. IL-19 polypeptides can be administered alone, or can be fused to cytotoxic moieties, and can be administered in conjunction with radiation or chemotherapeutic agents.
    Type: Grant
    Filed: April 8, 2003
    Date of Patent: July 24, 2007
    Assignee: ZymoGenetics, Inc.
    Inventors: Yasmin A. Chandrasekher, Patricia A. McKernan
  • FGF homolog polypeptides
    Patent number: 7247608
    Abstract: The present invention relates to polynucleotide and polypeptide molecules for zFGF-5 a novel member of the FGF family. The polypeptides, and polynucleotides encoding them, are proliferative for muscle cells and may be used for remodelling cardiac tissue and improving cardiac function. The present invention also includes antibodies to the zFGF-5 polypeptides.
    Type: Grant
    Filed: October 19, 2001
    Date of Patent: July 24, 2007
    Assignee: ZymoGenetics, Inc.
    Inventors: Theresa A. Deisher, Darrell C. Conklin, Fenella Raymond, Thomas R. Bukowski, Susan D. Holderman, Birgit Hansen, Paul O. Sheppard